Cyclosporine A steroid conjugates
US-9402913-B2 · Aug 2, 2016 · US
Isoquinoline-steroid conjugates and uses thereof
US11059789B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-11059789-B2 |
| Application number | US-201916557779-A |
| Country | US |
| Kind code | B2 |
| Filing date | Aug 30, 2019 |
| Priority date | Aug 31, 2018 |
| Publication date | Jul 13, 2021 |
| Grant date | Jul 13, 2021 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
Provided herein are compounds and pharmaceutical compositions useful in modulating kinase activity, and related diseases. Also provided herein are methods of treating an eye disease or disorder in a subject. Also provided herein are methods of reducing intraocular pressure in a subject. Also provided herein are methods of modulating kinase activity in a cell. Also provided herein are methods of making the compounds provided herein, and compounds useful for the preparation of the compounds provided herein.
First claim
Opening claim text (preview).
What is claimed is: 1. A compound selected from: or a pharmaceutically acceptable salt thereof. 2. A compound having the formula: R 8 —R 10 —R 11 or a pharmaceutically acceptable salt thereof, wherein R 8 is R 10 is and R 11 is 3. A compound having the formula: R 8 —R 10 —R 11 or a pharmaceutically acceptable salt thereof, wherein R 8 is R 10 is and R 11 is 4. A compound having the formula: R 8 —R 10 —R 11 or a pharmaceutically acceptable salt thereof, wherein R 8 is R 10 is and R 11 is 5. A compound having the formula: R 8 —R 10 —R 11 or a pharmaceutically acceptable salt thereof, wherein R 8 is R 10 is and R 11 is 6. A compound having the formula: R 8 —R 10 —R 11 or a pharmaceutically acceptable salt thereof, wherein R 8 is R 10 is and R 11 is 7. A compound having the formula: R 8 —R 10 —R 11 or a pharmaceutically acceptable salt thereof, wherein R 8 is R 10 is and R 11 is 8. A compound having the formula: R 8 —R 10 —R 11 or a pharmaceutically acceptable salt thereof, wherein R 8 is R 10 is and R 11 is 9. A compound having the formula: R 8 —R 10 -R 11 or a pharmaceutically acceptable salt thereof, wherein R 8 is R 10 is and R 11 is 10. A compound having the formula: R 8 —R 10 —R 11 or a pharmaceutically acceptable salt thereof, wherein R 8 is R 10 is and R 11 is 11. A composition, comprising the compound of claim 1 . 12. A composition, comprising the compound of claim 2 . 13. A composition, comprising the compound of claim 3 . 14. A composition, comprising the compound of claim 4 . 15. A composition, comprising the compound of claim 5 . 16. A composition, comprising the compound of claim 6 . 17. A composition, comprising the compound of claim 7 . 18. A composition, comprising the compound of claim 8 . 19. A composition, comprising the compound of claim 9 . 20. A composition, comprising the compound of claim 10 . 21. A pharmaceutical composition, comprising the compound of claim 1 , and a pharmaceutically acceptable carrier. 22. A pharmaceutical composition, comprising the compound of claim 2 , and a pharmaceutically acceptable carrier. 23. A pharmaceutical composition, comprising the compound of claim 3 , and a pharmaceutically acceptable carrier. 24. A pharmaceutical composition, comprising the compound of claim 4 , and a pharmaceutically acceptable carrier.
Assignees
Inventors
Classifications
at positions 16, 17 · CPC title
not condensed · CPC title
Antiglaucoma agents or miotics · CPC title
- C07D217/02Primary
with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines · CPC title
Ophthalmic agents · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US11059789B2 cover?
- Provided herein are compounds and pharmaceutical compositions useful in modulating kinase activity, and related diseases. Also provided herein are methods of treating an eye disease or disorder in a subject. Also provided herein are methods of reducing intraocular pressure in a subject. Also provided herein are methods of modulating kinase activity in a cell. Also provided herein are methods of…
- Who is the assignee on this patent?
- Aerie Pharmaceuticals Inc
- What technology area does this patent fall under?
- Primary CPC classification C07D217/02. Mapped technology areas include Chemistry & Metallurgy.
- When was this patent published?
- Publication date Tue Jul 13 2021 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 3 related publications on this page (citations in our corpus or others sharing the same primary CPC).